SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-018430
Filing Date
2020-01-29
Accepted
2020-01-29 16:19:31
Documents
13
Period of Report
2020-01-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d151496d8k.htm   iXBRL 8-K 30105
2 EX-99.1 d151496dex991.htm EX-99.1 9345
  Complete submission text file 0001193125-20-018430.txt   168246

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20200123.xsd EX-101.SCH 3067
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20200123_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20200123_pre.xml EX-101.PRE 11406
14 EXTRACTED XBRL INSTANCE DOCUMENT d151496d8k_htm.xml XML 3359
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 20558390
SIC: 2834 Pharmaceutical Preparations